- Home
- PPSI vs OTLK Comparison
PPSI vs OTLK Comparison
Compare PPSI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPSI
- OTLK
- Stock Information
- Founded
- PPSI 2008
- OTLK 2010
- Country
- PPSI United States
- OTLK United States
- Employees
- PPSI N/A
- OTLK N/A
- Industry
- PPSI Electrical Products
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPSI Industrials
- OTLK Health Care
- Exchange
- PPSI Nasdaq
- OTLK Nasdaq
- Market Cap
- PPSI 46.6M
- OTLK 42.8M
- IPO Year
- PPSI N/A
- OTLK 2016
- Fundamental
- Price
- PPSI $4.36
- OTLK $1.29
- Analyst Decision
- PPSI Strong Buy
- OTLK Buy
- Analyst Count
- PPSI 1
- OTLK 5
- Target Price
- PPSI $12.00
- OTLK $5.25
- AVG Volume (30 Days)
- PPSI 132.3K
- OTLK 1.8M
- Earning Date
- PPSI 11-13-2025
- OTLK 08-14-2025
- Dividend Yield
- PPSI 34.01%
- OTLK N/A
- EPS Growth
- PPSI N/A
- OTLK N/A
- EPS
- PPSI 2.91
- OTLK N/A
- Revenue
- PPSI $31,279,000.00
- OTLK $1,505,322.00
- Revenue This Year
- PPSI $27.32
- OTLK N/A
- Revenue Next Year
- PPSI $16.14
- OTLK $342.80
- P/E Ratio
- PPSI $1.52
- OTLK N/A
- Revenue Growth
- PPSI 105.82
- OTLK N/A
- 52 Week Low
- PPSI $2.25
- OTLK $0.79
- 52 Week High
- PPSI $7.00
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- PPSI 49.49
- OTLK 49.73
- Support Level
- PPSI $4.35
- OTLK $1.26
- Resistance Level
- PPSI $4.72
- OTLK $1.48
- Average True Range (ATR)
- PPSI 0.29
- OTLK 0.10
- MACD
- PPSI -0.04
- OTLK 0.00
- Stochastic Oscillator
- PPSI 19.61
- OTLK 21.87
About PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.